Allergic rhinitis is one of the most common human diseases that affect patients’ quality of of life. There has been a significant increase in incidence rates related to allergic rhinitis in the Russian Federation and the world. Second-generation antihistamines having high H1-receptor affinity constitute the main pharmacological group for the treatment of allergic rhinitis. The article presents an overview of Bilastin as a novel drug of the above group.

Allergic rhinitis is one of the most common human diseases and causes a deterioration of the quality of life. The prevalence of allergic rhinitis in the Russian Federation and in the world has increased significantly. The main pharmacological group in the treatment of allergic rhinitis is the 2nd generation antihistamines with high affinity for H1-receptors. The article presents an overview of the new representative of the abovementioned group of drugs - the drug bilastine (Nixar®).